Phase III
An analysis of efficacy outcomes by causative pathogens showed that clinical and microbiologic response rates for Zerbaxa were comparable to meropenem for Gram-negative respiratory tract pathogens.
Janssen’s Invokana could become the first diabetes medication to demonstrate reduction in progression to end-stage renal failure in Type 2 diabetes patients with chronic kidney disease.
Cambridge, Mass.-based Alnylam Pharmaceuticals indicated that its ENVISION Phase III trial of givosiran was positive for acute hepatic porphyria (AHP).
The combination of Opdivo and Yervoy actually fared worse than placebo, according to the data presented at the conference.
New data shows that patients are extremely satisfied with the medication. Data also showed that through 48 weeks, 84 percent of patients achieved undetectable viral loads, while 8 percent had virologic failures
As the International Liver Conference continues to unfold in Vienna, multiple companies are presenting data on potential treatments that can address numerous needs. BioSpace takes a look at some of the data.
Pharma and biotech companies from Asia to Europe provide updates on business and clinical activities.
Since taking over the role of chief executive officer at Bothell, Wash.-based Alder BioPharmaceuticals in June 2018, Robert Azelby has maintained his focus on moving the company closer to launching its first commercial product in the migraine treatment space.
Silver Spring, Maryland-based United Therapeutics announced that its esuberaprost tablet did not meet its primary endpoint in the BEAT Phase III clinical trial in patients with pulmonary arterial hypertension (PAH).
In five years it is estimated that about 25,000 people in the United States will develop bronchiolitis obliterans syndrome (BOS), which results in respiratory failure and death. But a late-stage treatment under development by Breath Therapeutics could be a possible remedy for this rare and dread disease.
PRESS RELEASES